Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Faculty Advisor Daniel DeSalvo, MD

Daniel DeSalvo, MD
Director of Strategic Collaboration, Texas Children’s Diabetes & Endocrine Care Center, Texas Children’s Hospital
Type 1 Diabetes Clinic Lead, Texas Children’s Hospital
Diabetes Transition Clinic Co-Lead, Texas Children’s Hospital
Assistant Professor, Baylor College of Medicine

Daniel DeSalvo joined the Texas Children’s Hospital Section of Pediatric Diabetes and Endocrinology in July 2015 after completing a postdoctoral fellowship at Stanford University. He serves as the Type 1 Diabetes Clinic Lead, Director of Strategic Collaboration for the Texas Children’s Diabetes & Endocrine Care Center, and TCH Diabetes Transition Clinic Co-Lead. His overarching career goal as a pediatric endocrinologist is to provide compassionate and comprehensive care to youth with diabetes, and to advance clinical care through patient-centered research and quality improvement endeavors. His clinical and research focus is on emerging diabetes technology and therapies (including continuous glucose monitoring and closed-loop automated insulin delivery systems) for improving clinical outcomes and reducing the burden of care. It was through his personal experience living with type 1 diabetes, and a desire to help others on a similar journey that motivated him to become a pediatric endocrinologist.

Perspective on Real-Time CGM:

“CGM has become the standard of care for diabetes management. At our site, Texas Children’s Hospital, which is a very heterogeneous population in Houston, our cross-sectional analysis showed that patients using CGM had a lower A1C than patients not using CGM, and that was true for both pump and injection users. As such, we have had a quality improvement project to try to improve the rates of CGM use. At this point, we now have over 70% of patients starting on CGM within 3 months of diagnosis. Additionally, Texas Medicaid is now covering CGM.”

Learn more from Dr. DeSalvo about the clinical and economic consequences of imprecise glycemic control in a new era of telehealth management in the CE activity: Presents: The Value of Continuous Glucose Monitoring during the COVID-19 Pandemic and New Era of Digital Healthcare